Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Abemaciclib in patients with p16ink4a negative, relapsed mesothelioma

Dean Fennell • 21 May 2021
ASCO 2021
Lung Cancer Mesothelioma Abemaciclib Rucaparib
MiST2

Malignant mesotheliomas frequently harbor loss of CDK2NA which is associated with shorter survival and may represent a novel treatment strategy for these patients. Dean A. Fennell, PhD, FRCP, University Hospitals of Leicester NHS Trust, Leicester, UK, presents findings of a Phase II study investigating the efficacy of abemaciclib, a CDK4/6 inhibitor in patients with p16ink4a negative relapsed mesothelioma in the MiST2 study (NCT03654833). This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

More from Dean Fennell

1:14
ATOMIC: treating mesothelioma with an arginine-degrading enzyme and combination chemotherapy
Dean Fennell • 27 Apr 2023
3:34
Role of immunotherapy in the management of mesothelioma
Dean Fennell • 31 Mar 2023
6:43
Personalized medicine in mesothelioma
Dean Fennell • 31 Mar 2023
1:11
Oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma
Dean Fennell • 21 May 2021

Related Videos

3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals